Background: Influenza causes significant morbidity and mortality, particularly among high-risk groups. More countries are recognizing the impact of influenza in children, as well as this age group’s important role in viral transmission. This is leading to the inclusion of this demographic in vaccination strategies.
In Portugal, the 2025/26 Seasonal Influenza Vaccination Campaign expanded to include children aged 6 months to 5 years, being free for those under 2 years of age. We aimed to study the impact of this new vaccination strategy in subjects under 18 years of age observed at a secondary level hospital in Lisbon, comparing positive influenza cases between seasons before and after the change.
Methods: A total of 5844 antigen and molecular respiratory pathogen panels were analysed (3062 from 2024/25 and 2782 from 2025/26), with 1507 tests positively identifying influenza A or B. Patients’ sex, age, and clinical data were collected to evaluate disease burden between both seasons. To compare differences between groups the Chi-Square Test was used, with a significance level of 0.05.
Results: Of the 1507 positive test results, 59.9% (n=903) were from the 2024/25 season and 40.1% (n=604) from the 2025/26 season, corresponding to 29.5% and 21,7% of all tests done in each season, respectively. We observed a statistically significant reduction (p < 0.001) in the number of positive cases between seasons (RRR=26,4%; CI 95%: 19,5%-32,7%). During the first season, Influenza B accounted for 517 cases (57.3%), while Influenza A made up the remaining 386 (42.7%). 2025/26 saw a drastic shift, with Influenza A accounting for 601 cases (99.5%) and Influenza B 3 cases (0.5%).
There were 64 hospitalizations, 51 in the first season and 13 in the latter, representing a 62% relative risk reduction (CI 95%: 30,6%-79,1%), which was statistically significant (p<0,001). The mean length of stay was 4 days and 3.5 days, respectively. The most common diagnoses in 2024/25 were acute myositis (25.5%) followed by pneumonia (15.7%). In 2025/26 pneumonia and acute otitis media (AOM) were the most common diagnoses, each accounting for 23.1%. In patients that didn’t require hospitalization, we observed 281 influenza with complications, 169 and 112 in the first and last seasons respectively (with no statistically significant difference). The most common diagnoses were AOM and pneumonia in both seasons, followed by acute myositis in 2024/25 and recurrent wheezing/asthma exacerbation in 2025/26.
Conclusions: In our sample, we observed a statistically significant reduction in the number of cases and rate of hospitalizations due to influenza after the inclusion of children in the vaccination campaign against influenza. Other factors such as virus characteristics, population immunity, and environment may also play a role in yearly disease activity. The 2024/25 influenza epidemic has been considered one of the most severe in recent years, so long-term surveillance is needed to establish the impact of the new vaccination strategy in Portugal.

